Author

Phil Jeffrey

Observed names: Jeffrey, P., P. Jeffrey, PHIL JEFFREY, Phil M. Jeffrey, Phillip Jeffrey

Institution: Bicycle Therapeutics (United Kingdom)

Observed institutions: European Bioinformatics Institute, Pfizer (United States), GlaxoSmithKline (United Kingdom), Pfizer (United Kingdom), Bicycle Therapeutics (United Kingdom), GlaxoSmithKline Research & Development Limited (United Kingdom), Wellcome Trust

ORCID: 0000-0003-4131-7218

Observed ORCID: 0000-0003-4131-7218

OpenAlex ID: A5011157656

Central Nervous System Drug Disposition: The Relationship between in Situ Brain Permeability and Brain Free Fraction

2007 · Scott G. Summerfield, Kevin Read, et al. · Journal of Pharmacology and Experimental Therapeutics · 292

Improving the in Vitro Prediction of in Vivo Central Nervous System Penetration: Integrating Permeability, P-glycoprotein Efflux, and Free Fractions in Blood and Brain

2006 · Scott G. Summerfield, Alexander J. Stevens, et al. · Journal of Pharmacology and Experimental Therapeutics · 181

5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): A Potent, Selective, and Orally Bioavailable 5-HT6 Receptor Antagonist

1999 · Steven M. Bromidge, Anthony M. Brown, et al. · Journal of Medicinal Chemistry · 173

The Practice of Medicinal Chemistry

2004 · P. Jeffrey · British Journal of Clinical Pharmacology · 159

Assessment of the blood–brain barrier in CNS drug discovery

2009 · Phil Jeffrey, Scott Summerfield · Neurobiology of Disease · 130

Receptor Occupancy and Brain Free Fraction

2009 · Jeanette Watson, Sara Wright, et al. · Drug Metabolism and Disposition · 120

Discovery of BT8009: A Nectin-4 Targeting Bicycle Toxin Conjugate for the Treatment of Cancer

2022 · Gemma E. Mudd, Heather Scott, et al. · Journal of Medicinal Chemistry · 114

Utility of metabolic stability screening: comparison ofin vitroandin vivoclearance

2001 · S. E. Clarke, P. Jeffrey · Xenobiotica · 114

Toward an improved prediction of humanin vivobrain penetration

2008 · S. G. Summerfield, A. J. Lucas, et al. · Xenobiotica · 106

BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors

2022 · Michael Rigby, Gavin Bennett, et al. · Molecular Cancer Therapeutics · 88

Challenges for blood–brain barrier (BBB) screening

2007 · P. Jeffrey, S. G. Summerfield · Xenobiotica · 82

Second Generation of Hydroxyethylamine BACE-1 Inhibitors: Optimizing Potency and Oral Bioavailability

2008 · Nicolas Charrier, Brian Clarke, et al. · Journal of Medicinal Chemistry · 68

Combining PET Biodistribution and Equilibrium Dialysis Assays to Assess the Free Brain Concentration and BBB Transport of CNS Drugs

2012 · Roger N Gunn, Scott G Summerfield, et al. · Journal of Cerebral Blood Flow & Metabolism · 62

Development of a P-Glycoprotein Knockout Model in Rodents to Define Species Differences in its Functional Effect at the Blood–brain Barrier

2006 · Leanne Cutler, Colin Howes, et al. · Journal of Pharmaceutical Sciences · 48

BT7480, a novel fully synthetic Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™) induces tumor localized CD137 agonism

2021 · Kristen Hurov, Johanna Lahdenranta, et al. · Journal for ImmunoTherapy of Cancer · 39

PDF

Pharmacokinetic (PK) assessment of BT1718: A phase I/II a study of BT1718, a first in class bicycle toxin conjugate (BTC), in patients (pts) with advanced solid tumours

2019 · N. Cook, U. Banerji, et al. · Annals of Oncology · 28

Discovery DMPK: changing paradigms in the eighties, nineties and noughties

2009 · Scott Summerfield, Phil Jeffrey · Expert Opinion on Drug Discovery · 24

Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology

2022 · Punit Upadhyaya, Julia Kristensson, et al. · Journal of Medicinal Chemistry · 21

In vitro prediction of brain penetration – a case for free thinking?

2006 · Scott G Summerfield, Phil Jeffrey · Expert Opinion on Drug Discovery · 18

BT5528-100 phase I/II study of the safety, pharmacokinetics, and preliminary clinical activity of BT5528 in patients with advanced malignancies associated with EphA2 expression.

2020 · Johanna C. Bendell, Judy Sing-Zan Wang, et al. · Journal of Clinical Oncology · 16

ADME SARfari: comparative genomics of drug metabolizing systems

2015 · Mark Davies, Nathan Dedman, et al. · Bioinformatics · 14

PDF

Expression and regulation of drug transporters in vertebrate neutrophils

2017 · Matthew J. Foulkes, Katherine M. Henry, et al. · Scientific Reports · 12

PDF

Approaches to assessing drug safety in the discovery phase

2010 · J. Allen, P. Jeffrey, et al. · Drugs of the Future · 10

Bioanalysis of the Bicycle®Toxin Conjugate BT5528 and Released Monomethyl Auristatin E via Liquid Chromatography–Tandem Mass Spectrometry

2023 · Joseph A Tweed, Fern Adams-Dam, et al. · Bioanalysis · 7

PF ‐07059013: A non‐covalent hemoglobin modulator favorably impacts disease state in a mouse model of sickle cell disease

2021 · Kelly M. Knee, Reema Jasuja, et al. · American Journal of Hematology · 7

PDF

Works count: 52

Citation count: 1,972

H-index: 18

I10-index: 23